JP2009519949A - 肥満症および関連する代謝性疾患の治療のための組成物および方法 - Google Patents

肥満症および関連する代謝性疾患の治療のための組成物および方法 Download PDF

Info

Publication number
JP2009519949A
JP2009519949A JP2008545850A JP2008545850A JP2009519949A JP 2009519949 A JP2009519949 A JP 2009519949A JP 2008545850 A JP2008545850 A JP 2008545850A JP 2008545850 A JP2008545850 A JP 2008545850A JP 2009519949 A JP2009519949 A JP 2009519949A
Authority
JP
Japan
Prior art keywords
peptide
fnx
nmx
polypeptide
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008545850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519949A5 (enExample
Inventor
アンドリュー・エイ・ヤング
サラ・エル・マックエイド
リチャード・ピットナー
ベド・スリバスタバ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richard Pittner
Sarah L Mcquaid
Amylin Pharmaceuticals LLC
Original Assignee
Richard Pittner
Sarah L Mcquaid
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richard Pittner, Sarah L Mcquaid, Amylin Pharmaceuticals LLC filed Critical Richard Pittner
Publication of JP2009519949A publication Critical patent/JP2009519949A/ja
Publication of JP2009519949A5 publication Critical patent/JP2009519949A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
JP2008545850A 2005-12-16 2006-12-15 肥満症および関連する代謝性疾患の治療のための組成物および方法 Pending JP2009519949A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75141205P 2005-12-16 2005-12-16
PCT/US2006/047953 WO2007075439A2 (en) 2005-12-16 2006-12-15 Compositions and methods for treating obesity and related metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009519949A true JP2009519949A (ja) 2009-05-21
JP2009519949A5 JP2009519949A5 (enExample) 2010-01-21

Family

ID=38218466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545850A Pending JP2009519949A (ja) 2005-12-16 2006-12-15 肥満症および関連する代謝性疾患の治療のための組成物および方法

Country Status (6)

Country Link
US (1) US20090209460A1 (enExample)
EP (1) EP1973953A2 (enExample)
JP (1) JP2009519949A (enExample)
AU (1) AU2006329836A1 (enExample)
CA (1) CA2634016A1 (enExample)
WO (1) WO2007075439A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
EP2120985B1 (en) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 peptides for use in the treatment of psychotic and anxiety disorders
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
RU2010114013A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение нейротрофического фактора для холинергических нейронов сетчатки (nfrcn) и хорионического гонадотропина бета (109-145) в качестве терапевтических средств
EP2187928A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of anti-inflammatory peptide 1 as a therapeutic agent
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5669728B2 (ja) * 2009-04-08 2015-02-12 武田薬品工業株式会社 ニューロメジンｕ誘導体
BRPI1011439B8 (pt) * 2009-05-08 2021-05-25 Yu Chongxi composição de alta penetração, composição farmacêutica, sistemas de aplicação terapêutico transdérmico e uso da referida composição
NO2462246T3 (enExample) 2009-09-28 2018-02-03
JP2013209295A (ja) 2010-10-13 2013-10-10 Takeda Chem Ind Ltd ペプチド誘導体
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
TWI754643B (zh) 2016-05-16 2022-02-11 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US12161694B2 (en) 2017-03-24 2024-12-10 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
WO2024149820A1 (en) 2023-01-12 2024-07-18 Boehringer Ingelheim International Gmbh Nmu receptor 2 agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081418A1 (en) * 2000-04-27 2001-11-01 Merck & Co., Inc. New neuromedin u receptor nmur2 and nucleotides encoding it

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002265497A (ja) * 2001-03-12 2002-09-18 Tadashi Hashimoto 生理活性ペプチドニューロメジンｕの高活性誘導体
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2592201C (en) * 2004-12-24 2016-08-09 Japan As Represented By The President Of National Cardiovascular Center Neuromedin s and the use thereof
EP1922336B1 (en) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2120985B1 (en) * 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 peptides for use in the treatment of psychotic and anxiety disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081418A1 (en) * 2000-04-27 2001-11-01 Merck & Co., Inc. New neuromedin u receptor nmur2 and nucleotides encoding it

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012019959; Ａｍｉｎｏ　Ａｃｉｄｓ．　２００３，　Ｖｏｌ．２５，　Ｎｏ．１，　ｐ．１０７-１１０ *

Also Published As

Publication number Publication date
WO2007075439A3 (en) 2007-12-06
CA2634016A1 (en) 2007-07-05
WO2007075439A2 (en) 2007-07-05
US20090209460A1 (en) 2009-08-20
AU2006329836A1 (en) 2007-07-05
EP1973953A2 (en) 2008-10-01

Similar Documents

Publication Publication Date Title
JP2009519949A (ja) 肥満症および関連する代謝性疾患の治療のための組成物および方法
AU2006230420B2 (en) Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
JP5820349B2 (ja) 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
US9085637B2 (en) Selective PYY compounds and uses thereof
US8263736B2 (en) Compounds and their effects on feeding behaviour
US8901073B2 (en) Compounds and their effects on feeding behaviour
AU2008257448B2 (en) Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
JP5743371B2 (ja) 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
US9018160B2 (en) Peptide tyrosine tyrosine analogues
US10583172B2 (en) HPYY(1-36) having a beta-homoarginine substitution at position 35
US20230285578A1 (en) Pth analogs for the treatment of hypoparathyroidism
JP2018522843A (ja) 選択的ｐｙｙ化合物及びその使用
JP2020500890A (ja) Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
US20110251126A1 (en) Intestinal treatment
US7928060B2 (en) Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
US20170137486A1 (en) Peptide yy (pyy) analogues
WO2022262837A1 (zh) 胰高血糖素类似物及其医药用途
AU2011361144A1 (en) Therapeutic agent for hyperthermia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121002